Signaling Pathway

Antibody-drug Conjugates

Antibody-drug Conjugates

Related Products

PDF File 0.26MB

Antibody-drug conjugates (ADCs) are a new class of highly potent biopharmaceutical drugs designed as a targeted therapy for the treatment of people with cancer. ADCs are complex molecules composed of an antibody linked, via a stable, chemical, linker with labile bonds, to a biological active cytotoxic (anticancer) payload or drug. By combining the unique targeting capabilities of monoclonal antibodies with the cancer-killing ability of cytotoxic drugs, antibody-drug conjugates allow sensitive discrimination between healthy and diseased tissue. This means that, in contrast to traditional chemotherapeutic agents, antibody-drug conjugates target and attack the cancer cell so that healthy cells are less severely affected.

Antibody-drug Conjugates Inhibitors & Modulators (12)

Product Name Catalog No. Brief Description
Acetylene-linker-Val-Cit-PABC-MMAE

HY-19812

Acetylene-linker-Val-Cit-PABC-MMAE consists the ADCs linker (Acetylene-linker-Val-Cit-PABC) and potent tubulin inhibitor (MMAE), Acetylene-linker-Val-Cit-PABC-MMAE is an antibody drug conjugate.

Cys-mcMMAD

HY-15750

Monomethyl auristatin D (MMAD), a potent tubulin inhibitor, is a toxin payload and antibody drug conjugate.

Fmoc-Val-Cit-PAB-MMAE

HY-19811

Fmoc-Val-Cit-PAB-MMAE consists the ADCs linker (Fmoc-Val-Cit-PAB) and potent tubulin inhibitor (MMAE), Fmoc-Val-Cit-PAB-MMAE is an antibody drug conjugate.

MAL-di-EG-Val-Cit-PAB-MMAE

HY-100567

MAL-di-EG-Val-Cit-PAB-MMAE consists the ADCs linker (MAL-di-EG-Val-Cit-PAB) and potent tubulin inhibitor (MMAE), MAL-di-EG-Val-Cit-PAB-MMAE is an antibody drug conjugate.

Mc-MMAD

HY-15740

Monomethyl auristatin D (MMAD), a potent tubulin inhibitor, is a toxin payload in antibody drug conjugate; Mc-MMAD is a protective group (maleimidocaproyl) -conjugated MMAD.

Mc-MMAE

HY-15741

Monomethyl auristatin E (MMAE), a potent tubulin inhibitor, is a toxin payload in antibody drug conjugate; Mc-MMAE is a protective group (maleimidocaproyl) -conjugated MMAE.

McMMAF

HY-15578

Mc-MMAF is a protective group-conjugated MMAF.

mDPR-Val-Cit-PAB-MMAE

HY-19813

mDPR-Val-Cit-PAB-MMAE consists the ADCs linker (mDPR-Val-Cit-PAB) and potent tubulin inhibitor (MMAE), mDPR-Val-Cit-PAB-MMAE is an antibody drug conjugate.

SuO-Val-Cit-PAB-MMAE

HY-100566

SuO-Val-Cit-PAB-MMAE consists of the ADCs linker (SuO-Val-Cit-PAB) and potent tubulin inhibitor (MMAE), SuO-Val-Cit-PAB-MMAE is an antibody-drug conjugate.

Val-Cit-PAB-MMAE

HY-100374

Val-Cit-PAB-MMAE is a potent tubulin inhibitor (MMAE), Val-Cit-PAB-MMAE is an antibody drug conjugate.

Vc-MMAD

HY-15742

Vc-MMAD consists the ADCs linker(Val-Cit) and potent tubulin inhibitor (MMAD), Vc-MMAD is an antibody drug conjugate.

VcMMAE

HY-15575

VcMMAE is an antibody-drug conjugate (ADC) with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE), linked via the lysosomally cleavable dipeptide, valine-citrulline (vc).